Click for best price
Hematological Cancers Market Size, Share 2022
hematologic cancer. Cancer that begins in blood-forming tissue, such as the bone marrow, or in the cells of the immune system. Examples of hematologic cancer are leukemia, lymphoma, and multiple myeloma. Also called blood cancer.
This report contains market size and forecasts of Hematological Cancers in Global, including the following market information:
Global Hematological Cancers Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Hematological Cancers market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Pharmacological Therapies Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Hematological Cancers include Karyopharm Therapeutics, Johnson & Johnson, Roche Diagnostics A/S, AbbVie, Novartis, Kite Pharma, Celgene Corporation, Abbott Laboratories and Beckman Coulter, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Hematological Cancers companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hematological Cancers Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Hematological Cancers Market Segment Percentages, by Type, 2021 (%)
Pharmacological Therapies
Stem Cell Transplantation
Surgery and Radiation Therapy
Anemia Treatment
Thrombosis Treatment
Neutopenia Treatment
Symptomatic treatment
Global Hematological Cancers Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Hematological Cancers Market Segment Percentages, by Application, 2021 (%)
Epidemiology
Pathophysiology of Leukemic Stem Cells
Kidney Diseases
Genetic Diseases
Other Diseases
Global Hematological Cancers Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Hematological Cancers Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hematological Cancers revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Hematological Cancers revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Karyopharm Therapeutics
Johnson & Johnson
Roche Diagnostics A/S
AbbVie
Novartis
Kite Pharma
Celgene Corporation
Abbott Laboratories
Beckman Coulter
HemoCue AB
C. R. Bard
Siemens AG
Sysmex
Mindray Medical International Limited
Bio-Rad Laboratories
The Medicine Company
Pharmacyclics
Horiba
DiagnoCure Inc.
Astellas Pharma US
| Report Attributes |
Report Details |
| Report Title |
Hematological Cancers Market - Global Outlook and Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
113 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Hematological Cancers Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Hematological Cancers Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Hematological Cancers Overall Market Size
2.1 Global Hematological Cancers Market Size: 2021 VS 2028
2.2 Global Hematological Cancers Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Hematological Cancers Players in Global Market
3.2 Top Global Hematological Cancers Companies Ranked by Revenue
3.3 Global Hematological Cancers Revenue by Companies
3.4 Top 3 and Top 5 Hematological Cancers Companies in Global Market, by Revenue in 2021
3.5 Global Companies Hematological Cancers Product Type
3.6 Tier 1, Tier 2 and Tier 3 Hematological Cancers Players in Global Market
3.6.1 List of Global Tier 1 Hematological Cancers Companies
3.6.2 List of Global Tier 2 and Tier 3 Hematological Cancers Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Hematological Cancers Market Size Markets, 2021 & 2028
4.1.2 Pharmacological Therapies
4.1.3 Stem Cell Transplantation
4.1.4 Surgery and Radiation Therapy
4.1.5 Anemia Treatment
4.1.6 Thrombosis Treatment
4.1.7 Neutopenia Treatment
4.1.8 Symptomatic treatment
4.2 By Type - Global Hematological Cancers Revenue & Forecasts
4.2.1 By Type - Global Hematological Cancers Revenue, 2017-2022
4.2.2 By Type - Global Hematological Cancers Revenue, 2023-2028
4.2.3 By Type - Global Hematological Cancers Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Hematological Cancers Market Size, 2021 & 2028
5.1.2 Epidemiology
5.1.3 Pathophysiology of Leukemic Stem Cells
5.1.4 Kidney Diseases
5.1.5 Genetic Diseases
5.1.6 Other Diseases
5.2 By Application - Global Hematological Cancers Revenue & Forecasts
5.2.1 By Application - Global Hematological Cancers Revenue, 2017-2022
5.2.2 By Application - Global Hematological Cancers Revenue, 2023-2028
5.2.3 By Application - Global Hematological Cancers Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Hematological Cancers Market Size, 2021 & 2028
6.2 By Region - Global Hematological Cancers Revenue & Forecasts
6.2.1 By Region - Global Hematological Cancers Revenue, 2017-2022
6.2.2 By Region - Global Hematological Cancers Revenue, 2023-2028
6.2.3 By Region - Global Hematological Cancers Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Hematological Cancers Revenue, 2017-2028
6.3.2 US Hematological Cancers Market Size, 2017-2028
6.3.3 Canada Hematological Cancers Market Size, 2017-2028
6.3.4 Mexico Hematological Cancers Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Hematological Cancers Revenue, 2017-2028
6.4.2 Germany Hematological Cancers Market Size, 2017-2028
6.4.3 France Hematological Cancers Market Size, 2017-2028
6.4.4 U.K. Hematological Cancers Market Size, 2017-2028
6.4.5 Italy Hematological Cancers Market Size, 2017-2028
6.4.6 Russia Hematological Cancers Market Size, 2017-2028
6.4.7 Nordic Countries Hematological Cancers Market Size, 2017-2028
6.4.8 Benelux Hematological Cancers Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Hematological Cancers Revenue, 2017-2028
6.5.2 China Hematological Cancers Market Size, 2017-2028
6.5.3 Japan Hematological Cancers Market Size, 2017-2028
6.5.4 South Korea Hematological Cancers Market Size, 2017-2028
6.5.5 Southeast Asia Hematological Cancers Market Size, 2017-2028
6.5.6 India Hematological Cancers Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Hematological Cancers Revenue, 2017-2028
6.6.2 Brazil Hematological Cancers Market Size, 2017-2028
6.6.3 Argentina Hematological Cancers Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Hematological Cancers Revenue, 2017-2028
6.7.2 Turkey Hematological Cancers Market Size, 2017-2028
6.7.3 Israel Hematological Cancers Market Size, 2017-2028
6.7.4 Saudi Arabia Hematological Cancers Market Size, 2017-2028
6.7.5 UAE Hematological Cancers Market Size, 2017-2028
7 Players Profiles
7.1 Karyopharm Therapeutics
7.1.1 Karyopharm Therapeutics Corporate Summary
7.1.2 Karyopharm Therapeutics Business Overview
7.1.3 Karyopharm Therapeutics Hematological Cancers Major Product Offerings
7.1.4 Karyopharm Therapeutics Hematological Cancers Revenue in Global Market (2017-2022)
7.1.5 Karyopharm Therapeutics Key News
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Corporate Summary
7.2.2 Johnson & Johnson Business Overview
7.2.3 Johnson & Johnson Hematological Cancers Major Product Offerings
7.2.4 Johnson & Johnson Hematological Cancers Revenue in Global Market (2017-2022)
7.2.5 Johnson & Johnson Key News
7.3 Roche Diagnostics A/S
7.3.1 Roche Diagnostics A/S Corporate Summary
7.3.2 Roche Diagnostics A/S Business Overview
7.3.3 Roche Diagnostics A/S Hematological Cancers Major Product Offerings
7.3.4 Roche Diagnostics A/S Hematological Cancers Revenue in Global Market (2017-2022)
7.3.5 Roche Diagnostics A/S Key News
7.4 AbbVie
7.4.1 AbbVie Corporate Summary
7.4.2 AbbVie Business Overview
7.4.3 AbbVie Hematological Cancers Major Product Offerings
7.4.4 AbbVie Hematological Cancers Revenue in Global Market (2017-2022)
7.4.5 AbbVie Key News
7.5 Novartis
7.5.1 Novartis Corporate Summary
7.5.2 Novartis Business Overview
7.5.3 Novartis Hematological Cancers Major Product Offerings
7.5.4 Novartis Hematological Cancers Revenue in Global Market (2017-2022)
7.5.5 Novartis Key News
7.6 Kite Pharma
7.6.1 Kite Pharma Corporate Summary
7.6.2 Kite Pharma Business Overview
7.6.3 Kite Pharma Hematological Cancers Major Product Offerings
7.6.4 Kite Pharma Hematological Cancers Revenue in Global Market (2017-2022)
7.6.5 Kite Pharma Key News
7.7 Celgene Corporation
7.7.1 Celgene Corporation Corporate Summary
7.7.2 Celgene Corporation Business Overview
7.7.3 Celgene Corporation Hematological Cancers Major Product Offerings
7.7.4 Celgene Corporation Hematological Cancers Revenue in Global Market (2017-2022)
7.7.5 Celgene Corporation Key News
7.8 Abbott Laboratories
7.8.1 Abbott Laboratories Corporate Summary
7.8.2 Abbott Laboratories Business Overview
7.8.3 Abbott Laboratories Hematological Cancers Major Product Offerings
7.8.4 Abbott Laboratories Hematological Cancers Revenue in Global Market (2017-2022)
7.8.5 Abbott Laboratories Key News
7.9 Beckman Coulter
7.9.1 Beckman Coulter Corporate Summary
7.9.2 Beckman Coulter Business Overview
7.9.3 Beckman Coulter Hematological Cancers Major Product Offerings
7.9.4 Beckman Coulter Hematological Cancers Revenue in Global Market (2017-2022)
7.9.5 Beckman Coulter Key News
7.10 HemoCue AB
7.10.1 HemoCue AB Corporate Summary
7.10.2 HemoCue AB Business Overview
7.10.3 HemoCue AB Hematological Cancers Major Product Offerings
7.10.4 HemoCue AB Hematological Cancers Revenue in Global Market (2017-2022)
7.10.5 HemoCue AB Key News
7.11 C. R. Bard
7.11.1 C. R. Bard Corporate Summary
7.11.2 C. R. Bard Business Overview
7.11.3 C. R. Bard Hematological Cancers Major Product Offerings
7.11.4 C. R. Bard Hematological Cancers Revenue in Global Market (2017-2022)
7.11.5 C. R. Bard Key News
7.12 Siemens AG
7.12.1 Siemens AG Corporate Summary
7.12.2 Siemens AG Business Overview
7.12.3 Siemens AG Hematological Cancers Major Product Offerings
7.12.4 Siemens AG Hematological Cancers Revenue in Global Market (2017-2022)
7.12.5 Siemens AG Key News
7.13 Sysmex
7.13.1 Sysmex Corporate Summary
7.13.2 Sysmex Business Overview
7.13.3 Sysmex Hematological Cancers Major Product Offerings
7.13.4 Sysmex Hematological Cancers Revenue in Global Market (2017-2022)
7.13.5 Sysmex Key News
7.14 Mindray Medical International Limited
7.14.1 Mindray Medical International Limited Corporate Summary
7.14.2 Mindray Medical International Limited Business Overview
7.14.3 Mindray Medical International Limited Hematological Cancers Major Product Offerings
7.14.4 Mindray Medical International Limited Hematological Cancers Revenue in Global Market (2017-2022)
7.14.5 Mindray Medical International Limited Key News
7.15 Bio-Rad Laboratories
7.15.1 Bio-Rad Laboratories Corporate Summary
7.15.2 Bio-Rad Laboratories Business Overview
7.15.3 Bio-Rad Laboratories Hematological Cancers Major Product Offerings
7.15.4 Bio-Rad Laboratories Hematological Cancers Revenue in Global Market (2017-2022)
7.15.5 Bio-Rad Laboratories Key News
7.16 The Medicine Company
7.16.1 The Medicine Company Corporate Summary
7.16.2 The Medicine Company Business Overview
7.16.3 The Medicine Company Hematological Cancers Major Product Offerings
7.16.4 The Medicine Company Hematological Cancers Revenue in Global Market (2017-2022)
7.16.5 The Medicine Company Key News
7.17 Pharmacyclics
7.17.1 Pharmacyclics Corporate Summary
7.17.2 Pharmacyclics Business Overview
7.17.3 Pharmacyclics Hematological Cancers Major Product Offerings
7.17.4 Pharmacyclics Hematological Cancers Revenue in Global Market (2017-2022)
7.17.5 Pharmacyclics Key News
7.18 Horiba
7.18.1 Horiba Corporate Summary
7.18.2 Horiba Business Overview
7.18.3 Horiba Hematological Cancers Major Product Offerings
7.18.4 Horiba Hematological Cancers Revenue in Global Market (2017-2022)
7.18.5 Horiba Key News
7.19 DiagnoCure Inc.
7.19.1 DiagnoCure Inc. Corporate Summary
7.19.2 DiagnoCure Inc. Business Overview
7.19.3 DiagnoCure Inc. Hematological Cancers Major Product Offerings
7.19.4 DiagnoCure Inc. Hematological Cancers Revenue in Global Market (2017-2022)
7.19.5 DiagnoCure Inc. Key News
7.20 Astellas Pharma US
7.20.1 Astellas Pharma US Corporate Summary
7.20.2 Astellas Pharma US Business Overview
7.20.3 Astellas Pharma US Hematological Cancers Major Product Offerings
7.20.4 Astellas Pharma US Hematological Cancers Revenue in Global Market (2017-2022)
7.20.5 Astellas Pharma US Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Hematological Cancers Market Opportunities & Trends in Global Market
Table 2. Hematological Cancers Market Drivers in Global Market
Table 3. Hematological Cancers Market Restraints in Global Market
Table 4. Key Players of Hematological Cancers in Global Market
Table 5. Top Hematological Cancers Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Hematological Cancers Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Hematological Cancers Revenue Share by Companies, 2017-2022
Table 8. Global Companies Hematological Cancers Product Type
Table 9. List of Global Tier 1 Hematological Cancers Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Hematological Cancers Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Hematological Cancers Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Hematological Cancers Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Hematological Cancers Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application ? Global Hematological Cancers Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Hematological Cancers Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Hematological Cancers Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global Hematological Cancers Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Hematological Cancers Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Hematological Cancers Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Hematological Cancers Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Hematological Cancers Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Hematological Cancers Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Hematological Cancers Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Hematological Cancers Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Hematological Cancers Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Hematological Cancers Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Hematological Cancers Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Hematological Cancers Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Hematological Cancers Revenue, (US$, Mn), 2023-2028
Table 30. Karyopharm Therapeutics Corporate Summary
Table 31. Karyopharm Therapeutics Hematological Cancers Product Offerings
Table 32. Karyopharm Therapeutics Hematological Cancers Revenue (US$, Mn), (2017-2022)
Table 33. Johnson & Johnson Corporate Summary
Table 34. Johnson & Johnson Hematological Cancers Product Offerings
Table 35. Johnson & Johnson Hematological Cancers Revenue (US$, Mn), (2017-2022)
Table 36. Roche Diagnostics A/S Corporate Summary
Table 37. Roche Diagnostics A/S Hematological Cancers Product Offerings
Table 38. Roche Diagnostics A/S Hematological Cancers Revenue (US$, Mn), (2017-2022)
Table 39. AbbVie Corporate Summary
Table 40. AbbVie Hematological Cancers Product Offerings
Table 41. AbbVie Hematological Cancers Revenue (US$, Mn), (2017-2022)
Table 42. Novartis Corporate Summary
Table 43. Novartis Hematological Cancers Product Offerings
Table 44. Novartis Hematological Cancers Revenue (US$, Mn), (2017-2022)
Table 45. Kite Pharma Corporate Summary
Table 46. Kite Pharma Hematological Cancers Product Offerings
Table 47. Kite Pharma Hematological Cancers Revenue (US$, Mn), (2017-2022)
Table 48. Celgene Corporation Corporate Summary
Table 49. Celgene Corporation Hematological Cancers Product Offerings
Table 50. Celgene Corporation Hematological Cancers Revenue (US$, Mn), (2017-2022)
Table 51. Abbott Laboratories Corporate Summary
Table 52. Abbott Laboratories Hematological Cancers Product Offerings
Table 53. Abbott Laboratories Hematological Cancers Revenue (US$, Mn), (2017-2022)
Table 54. Beckman Coulter Corporate Summary
Table 55. Beckman Coulter Hematological Cancers Product Offerings
Table 56. Beckman Coulter Hematological Cancers Revenue (US$, Mn), (2017-2022)
Table 57. HemoCue AB Corporate Summary
Table 58. HemoCue AB Hematological Cancers Product Offerings
Table 59. HemoCue AB Hematological Cancers Revenue (US$, Mn), (2017-2022)
Table 60. C. R. Bard Corporate Summary
Table 61. C. R. Bard Hematological Cancers Product Offerings
Table 62. C. R. Bard Hematological Cancers Revenue (US$, Mn), (2017-2022)
Table 63. Siemens AG Corporate Summary
Table 64. Siemens AG Hematological Cancers Product Offerings
Table 65. Siemens AG Hematological Cancers Revenue (US$, Mn), (2017-2022)
Table 66. Sysmex Corporate Summary
Table 67. Sysmex Hematological Cancers Product Offerings
Table 68. Sysmex Hematological Cancers Revenue (US$, Mn), (2017-2022)
Table 69. Mindray Medical International Limited Corporate Summary
Table 70. Mindray Medical International Limited Hematological Cancers Product Offerings
Table 71. Mindray Medical International Limited Hematological Cancers Revenue (US$, Mn), (2017-2022)
Table 72. Bio-Rad Laboratories Corporate Summary
Table 73. Bio-Rad Laboratories Hematological Cancers Product Offerings
Table 74. Bio-Rad Laboratories Hematological Cancers Revenue (US$, Mn), (2017-2022)
Table 75. The Medicine Company Corporate Summary
Table 76. The Medicine Company Hematological Cancers Product Offerings
Table 77. The Medicine Company Hematological Cancers Revenue (US$, Mn), (2017-2022)
Table 78. Pharmacyclics Corporate Summary
Table 79. Pharmacyclics Hematological Cancers Product Offerings
Table 80. Pharmacyclics Hematological Cancers Revenue (US$, Mn), (2017-2022)
Table 81. Horiba Corporate Summary
Table 82. Horiba Hematological Cancers Product Offerings
Table 83. Horiba Hematological Cancers Revenue (US$, Mn), (2017-2022)
Table 84. DiagnoCure Inc. Corporate Summary
Table 85. DiagnoCure Inc. Hematological Cancers Product Offerings
Table 86. DiagnoCure Inc. Hematological Cancers Revenue (US$, Mn), (2017-2022)
Table 87. Astellas Pharma US Corporate Summary
Table 88. Astellas Pharma US Hematological Cancers Product Offerings
Table 89. Astellas Pharma US Hematological Cancers Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Hematological Cancers Segment by Type in 2021
Figure 2. Hematological Cancers Segment by Application in 2021
Figure 3. Global Hematological Cancers Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Hematological Cancers Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Hematological Cancers Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Hematological Cancers Revenue in 2021
Figure 8. By Type - Global Hematological Cancers Revenue Market Share, 2017-2028
Figure 9. By Application - Global Hematological Cancers Revenue Market Share, 2017-2028
Figure 10. By Region - Global Hematological Cancers Revenue Market Share, 2017-2028
Figure 11. By Country - North America Hematological Cancers Revenue Market Share, 2017-2028
Figure 12. US Hematological Cancers Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Hematological Cancers Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Hematological Cancers Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Hematological Cancers Revenue Market Share, 2017-2028
Figure 16. Germany Hematological Cancers Revenue, (US$, Mn), 2017-2028
Figure 17. France Hematological Cancers Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Hematological Cancers Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Hematological Cancers Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Hematological Cancers Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Hematological Cancers Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Hematological Cancers Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Hematological Cancers Revenue Market Share, 2017-2028
Figure 24. China Hematological Cancers Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Hematological Cancers Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Hematological Cancers Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Hematological Cancers Revenue, (US$, Mn), 2017-2028
Figure 28. India Hematological Cancers Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Hematological Cancers Revenue Market Share, 2017-2028
Figure 30. Brazil Hematological Cancers Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Hematological Cancers Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Hematological Cancers Revenue Market Share, 2017-2028
Figure 33. Turkey Hematological Cancers Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Hematological Cancers Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Hematological Cancers Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Hematological Cancers Revenue, (US$, Mn), 2017-2028
Figure 37. Karyopharm Therapeutics Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Johnson & Johnson Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Roche Diagnostics A/S Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. AbbVie Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Novartis Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Kite Pharma Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Celgene Corporation Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Abbott Laboratories Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Beckman Coulter Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. HemoCue AB Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. C. R. Bard Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Siemens AG Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Sysmex Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Mindray Medical International Limited Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. Bio-Rad Laboratories Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 52. The Medicine Company Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 53. Pharmacyclics Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 54. Horiba Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 55. DiagnoCure Inc. Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 56. Astellas Pharma US Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
